Following these proceedings, BTIG Research initiated its Mustang Bio Inc [MBIO] rating to a Buy in a research note published on May 18, 2021; the price target was $11. A number of analysts have revised their coverage, including B. Riley FBR’s analysts, who began to cover the stock in early October with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering MBIO with “an Overweight” recommendation on November 20, 2019. H.C. Wainwright started covering the stock on August 13, 2019. It rated MBIO as “a Buy”.
Price Performance Review of MBIO
On Tuesday, Mustang Bio Inc [NASDAQ:MBIO] saw its stock fall -35.77% to $0.14. Over the last five days, the stock has lost -32.80%. Mustang Bio Inc shares have fallen nearly -18.76% since the year began. Nevertheless, the stocks have fallen -89.43% over the past one year. While a 52-week high of $1.52 was reached on 01/02/25, a 52-week low of $0.13 was recorded on 01/14/25. SMA at 50 days reached $0.2080, while 200 days put it at $0.3100.
Levels Of Support And Resistance For MBIO Stock
The 24-hour chart illustrates a support level at 0.1322, which if violated will result in even more drops to 0.1205. On the upside, there is a resistance level at 0.1627. A further resistance level may holdings at 0.1815. The Relative Strength Index (RSI) on the 14-day chart is 36.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0108, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.53%. Stochastics %K at 20.23% indicates the stock is a holding.
How much short interest is there in Mustang Bio Inc?
A steep rise in short interest was recorded in Mustang Bio Inc stocks on 2024-12-31, growing by 0.1 million shares to a total of 0.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 0.25 million shares. There was a rise of 28.32%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 21, 2019 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $7 price target.
